D.A. Davidson & CO. Increases Stake in Celgene Corporation (CELG)

D.A. Davidson & CO. boosted its stake in Celgene Corporation (NASDAQ:CELG) by 8.8% during the third quarter, Holdings Channel reports. The institutional investor owned 87,437 shares of the biopharmaceutical company’s stock after buying an additional 7,090 shares during the period. D.A. Davidson & CO.’s holdings in Celgene Corporation were worth $9,133,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. First Financial Corp IN boosted its stake in shares of Celgene Corporation by 30.9% in the third quarter. First Financial Corp IN now owns 967 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 228 shares in the last quarter. Smithfield Trust Co. boosted its stake in shares of Celgene Corporation by 12.5% in the second quarter. Smithfield Trust Co. now owns 1,282 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 142 shares in the last quarter. Jolley Asset Management LLC boosted its stake in shares of Celgene Corporation by 2.1% in the third quarter. Jolley Asset Management LLC now owns 1,240 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 25 shares in the last quarter. Integrated Investment Consultants LLC boosted its stake in shares of Celgene Corporation by 2.2% in the third quarter. Integrated Investment Consultants LLC now owns 1,369 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 30 shares in the last quarter. Finally, Cornerstone Advisors Inc. boosted its stake in shares of Celgene Corporation by 202.8% in the third quarter. Cornerstone Advisors Inc. now owns 1,320 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 884 shares in the last quarter. 77.68% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Shares of Celgene Corporation (NASDAQ:CELG) opened at 116.42 on Tuesday. The firm has a market cap of $90.25 billion, a PE ratio of 46.76 and a beta of 1.74. Celgene Corporation has a 1-year low of $94.39 and a 1-year high of $127.00. The stock’s 50 day moving average is $116.07 and its 200-day moving average is $111.82.

Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, January 26th. The biopharmaceutical company reported $1.61 earnings per share for the quarter, beating analysts’ consensus estimates of $1.59 by $0.02. The business had revenue of $2.98 billion for the quarter, compared to the consensus estimate of $3.03 billion. Celgene Corporation had a net margin of 17.80% and a return on equity of 77.95%. Celgene Corporation’s quarterly revenue was up 16.3% on a year-over-year basis. During the same period last year, the firm posted $1.18 earnings per share. Analysts expect that Celgene Corporation will post $7.22 earnings per share for the current year.

“D.A. Davidson & CO. Increases Stake in Celgene Corporation (CELG)” was first reported by sleekmoney and is owned by of sleekmoney. If you are viewing this article on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this article can be accessed at http://sleekmoney.com/d-a-davidson-co-increases-stake-in-celgene-corporation-celg/1659780.html.

CELG has been the topic of several research analyst reports. Mizuho initiated coverage on shares of Celgene Corporation in a research note on Monday, November 7th. They set a “buy” rating and a $130.00 price objective on the stock. Zacks Investment Research raised shares of Celgene Corporation from a “hold” rating to a “buy” rating and set a $117.00 price objective on the stock in a research note on Wednesday, November 2nd. BTIG Research reaffirmed a “buy” rating and set a $138.00 price objective on shares of Celgene Corporation in a research note on Monday, October 31st. Vetr cut shares of Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $115.50 price objective on the stock. in a research note on Monday, October 31st. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $159.00 price objective on shares of Celgene Corporation in a research note on Friday, October 28th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, twenty-four have assigned a buy rating and one has issued a strong buy rating to the company. Celgene Corporation currently has an average rating of “Buy” and an average price target of $138.78.

Celgene Corporation Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/d-a-davidson-co-increases-stake-in-celgene-corporation-celg/1659780.html

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *